Molecular Imaging Program at Stanford, Department of Radiology, School of Medicine, Stanford University, Stanford, California, USA.
Institute for Stem Cell Biology and Regenerative Medicine, School of Medicine, Stanford University, Stanford, California, USA.
Am J Sports Med. 2021 Jun;49(7):1861-1870. doi: 10.1177/03635465211005754. Epub 2021 Apr 19.
The transplantation of mesenchymal stem cells (MSCs) into cartilage defects has led to variable cartilage repair outcomes. Previous in vitro studies have shown that ascorbic acid and reduced iron independently can improve the chondrogenic differentiation of MSCs. However, the combined effect of ascorbic acid and iron supplementation on MSC differentiation has not been investigated.
To investigate the combined in vivo effects of ascorbic acid and a US Food and Drug Administration (FDA)-approved iron supplement on MSC-mediated cartilage repair in mature Göttingen minipigs.
Controlled laboratory study.
We pretreated bone marrow-derived MSCs with ascorbic acid and the FDA-approved iron supplement ferumoxytol and then transplanted the MSCs into full-thickness cartilage defects in the distal femurs of Göttingen minipigs. Untreated cartilage defects served as negative controls. We evaluated the cartilage repair site with magnetic resonance imaging at 4 and 12 weeks after MSC implantation, followed by histological examination and immunofluorescence staining at 12 weeks.
Ascorbic acid plus iron-pretreated MSCs demonstrated a significantly better MOCART (magnetic resonance observation of cartilage repair tissue) score (73.8 ± 15.5), better macroscopic cartilage regeneration score according to the International Cartilage Repair Society (8.6 ± 2.0), better Pineda score (2.9 ± 0.8), and larger amount of collagen type II (28,469 ± 21,313) compared with untreated controls (41.3 ± 2.5, 1.8 ± 2.9, 12.8 ± 1.9, and 905 ± 1326, respectively). The obtained scores were also better than scores previously reported in the same animal model for MSC implants without ascorbic acid.
Pretreatment of MSCs with ascorbic acid and an FDA-approved iron supplement improved the chondrogenesis of MSCs and led to hyaline-like cartilage regeneration in the knee joints of minipigs.
Ascorbic acid and iron supplements are immediately clinically applicable. Thus, these results, in principle, could be translated into clinical applications.
间充质干细胞(MSCs)移植到软骨缺损部位可导致不同的软骨修复结果。先前的体外研究表明,抗坏血酸和还原铁可以独立地改善 MSCs 的软骨分化。然而,抗坏血酸和铁补充剂联合对 MSC 分化的影响尚未得到研究。
研究抗坏血酸和美国食品和药物管理局(FDA)批准的铁补充剂联合对成熟哥廷根小型猪 MSC 介导的软骨修复的体内联合作用。
对照实验室研究。
我们用抗坏血酸和 FDA 批准的铁补充剂 ferumoxytol 预处理骨髓来源的 MSCs,然后将 MSCs 移植到哥廷根小型猪的股骨远端全层软骨缺损部位。未处理的软骨缺损作为阴性对照。在 MSC 植入后 4 周和 12 周,我们通过磁共振成像(MRI)评估软骨修复部位,然后在 12 周时进行组织学检查和免疫荧光染色。
抗坏血酸加铁预处理的 MSCs 表现出明显更好的 MOCART(磁共振观察软骨修复组织)评分(73.8±15.5)、根据国际软骨修复协会(International Cartilage Repair Society)的更好的大体软骨再生评分(8.6±2.0)、更好的 Pineda 评分(2.9±0.8)和更大的 II 型胶原量(28469±21313),与未处理的对照组相比(41.3±2.5、1.8±2.9、12.8±1.9 和 905±1326)。获得的评分也优于同一动物模型中以前报道的无抗坏血酸的 MSC 植入物的评分。
用抗坏血酸和 FDA 批准的铁补充剂预处理 MSCs 可改善 MSCs 的软骨生成,并导致小型猪膝关节的透明样软骨再生。
抗坏血酸和铁补充剂具有立即的临床适用性。因此,这些结果原则上可以转化为临床应用。